

GLENMARK Pharmaceuticals Australia Launches ZONOFADÉ™

A Scientifically Formulated Diabetes Skincare Range to Nourish, Protect & Restore Skin Health

Sydney, July 2025 – GLENMARK Pharmaceuticals (Australia) Pty Ltd., a subsidiary of GLENMARK Pharmaceuticals Ltd. a global, research-driven pharmaceutical company, is proud to announce the Australian launch of ZONOFADÉ* its pioneering diabetes skincare range, formulated to meet the unique needs of people living with diabetes.¹

This new range, which includes three purpose-driven products, **DAILY SKIN CONDITIONER, WOUND SUPPORT GEL, and SKIN BARRIER SUPPORT CREAM**, is powered by PTT-6™, a patented stem cell complex that has been scientifically formulated to support the skin barrier function and resilience of diabetic skin.^{1,2}

Each product has been developed with key ingredients including growth factors, collagen, hyaluronic acid, curcumin, and urea. This results in a powerful diabetic skin care range delivering targeted hydration, nourishment, and protection to skin that is often fragile, dry, or slow to heal due to the impact of diabetes. Key to the potency of this range is PTT-6™, a patented stem cell complex.†

Addressing a common, but often overlooked, issue

Skin complications are among the most common and under-recognised consequences of diabetes, affecting up to 70% of diabetic patients.^{3,4} Proactively managing skin integrity through a regular and comprehensive skincare regimen is key to reducing the risk of cracks, lesions, infections and impaired healing.^{5,6}

The ZONOFADÉ diabetes skincare range is designed to address various needs:

1. **PREVENT: DAILY SKIN CONDITIONER** Maintains the skin's protective barrier and hydrates dry, cracked or fragile areas prone to breakdown.^{1,2,7}
2. **PROTECT: WOUND SUPPORT GEL** Protects healthy skin around open wounds by supporting hydration and skin barrier function.^{1,2,7}
3. **RESTORE: SKIN BARRIER SUPPORT CREAM** Supports and nourishes skin around healed wounds, promoting skin resilience and recovery.^{1,8}

Each product is backed by dermatological experience across a range of leading in-hospital skin clinics,¹ making it an ideal tool for pharmacists, diabetes educators, and healthcare professionals who want to do more to help their diabetic patients improve their skin health and overall wellbeing.

A Milestone in GLENMARK's APAC Expansion

The launch of the ZONOFADÉ diabetes skincare range in Australia marks a significant step forward in GLENMARK's commitment to the Australian market and its growing presence in the Asia-Pacific region. This follows the successful Australian launch of SUPIROCIN™ antibacterial cream by

GLENMARK in 2024, and underscores its continued investment in broadening dermatology options for patients in Australia.

"We're thrilled to bring the innovative ZONOFADÉ skincare range to Australian for patients living with diabetes," said Michael Moffitt, Country Manager, Australia & New Zealand at GLENMARK Pharmaceuticals. "By offering a science-led, targeted skincare range powered by PTT-6™, we're enabling consumers and healthcare providers to take proactive steps in mitigating one of the most prevalent concerns of diabetes patients. This is more than skincare, for vulnerable diabetic patients it's about restoring confidence, comfort and control in the daily maintenance of their skin."

For Ordering & Distribution

Wholesalers: Contact Healthcare Logistics (HCL) on 1300 364 586

Pharmacies: Pharmabroker Sales on 02 8878 9733.

Find Out More: www.zonofade.com.au

Local Media Contact: Michael Moffitt, Country Manager, Australia & New Zealand e) Michael.Moffitt@glenmarkpharma.com m) +61 412 387 087	Global Media Contact: Udaykumar Murthy, DGM – Corporate Communications e) corpcomm@glenmarkpharma.com m) +91-9960377617
--	--

About GLENMARK Pharmaceuticals Ltd.

GLENMARK Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led global pharmaceutical organisation with a presence across Branded, Generics, and OTC categories. Its core therapeutic areas include dermatology, respiratory and oncology. With ten manufacturing sites across four continents and operations in over 80 countries, the GLENMARK ranks among the top global performers in R&D-driven pharmaceutical innovation. GLENMARK is recognised in In Vivo/Scrip 100's list of Top 100 Companies Ranked by R&D and Sales (2022), and in the Top 50 Generics and Biosimilars Companies by Generics Bulletin. GLENMARK is also one of only two Indian pharmaceutical companies to have its greenhouse gas emissions reduction targets approved by the Science Based Target initiative (SBTi). Over the past decade, the organisation has impacted more than 2.9 million lives through its CSR efforts. For more information, visit www.glenmark.com.au Follow us on LinkedIn [Glenmark Pharmaceuticals] and Instagram [glenmark_pharma]

* ZONOFADÉ™ is also known as Sollagen™ in other markets † Ethically sourced from umbilical cords of red deer raised for velvet antler in New Zealand **References:** 1. Data on file 2. Ong CT *et al. J Drugs Dermatol* 2023;22(1):82–89. 3. Salari N *et al. J Diabetes Metab Disord* 2020;19(2):1909–1916. 4. Demirsen DD *et al. Am J Clin Dermatol* 2014;15(1):65–70. 5. Chen VY *et al. Wound Repair Regen* 2023;31(5):700–712. 6. David P *et al. Cureus* 2023;15(5):e38961. 7. Hoss E *et al. J Drugs Dermatol* 2020;19(11):1044–1048. 8. Bains P, Kaur S. *J Cutan Aesthet Surg* 2023;16:14–20. **G-INPLMS32536**